Gennex Laboratories Ltd — Important, 30-05-2026: Company Update

Gennex Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by its Secretarial Auditor, detailed a past delay in seeking trading approval for 1.55 crore new equity shares. This resulted in a penalty of Rs. 2.29 Cr, with a waiver application currently under process due to RTA/CDSL delays. A previous non-compliance regarding Board composition also led to a paid penalty of Rs. 0.01 Cr. Despite these past issues, the audit confirmed general compliance across other key corporate governance standards. This clarifies the company's adherence to regulatory norms and the financial implications of past deviations.